Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Pipeline Review, H2 2018

Publisher Name :
Date: 11-Sep-2018
No. of pages: 60

Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Pipeline Review, H2 2018

Summary

Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Plasminogen activator inhibitor-1 (PAI-1) also known as endothelial plasminogen activator inhibitor or is a protein that encodes by the SERPINE1 gene. Elevated PAI-1 is a risk factor for thrombosis and atherosclerosis. PAI-1 is mainly produced by the endothelium and also by other tissue types, such as adipose tissue. PAI-1 inhibits the serine proteases tPA and urokinase and hence inhibit the physiological process that degrades blood clots. PAI-1 inhibits the activity of matrix metalloproteinases (important role in invasion of malignant cells across the basal lamina).

Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) pipeline Target constitutes close to 10 molecules. Out of which approximately 3 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III and Preclinical stages are 1 and 2 respectively. Similarly, the universities portfolio in Phase II and Preclinical stages comprises 1 and 6 molecules, respectively.

Report covers products from therapy areas Cardiovascular, Genito Urinary System And Sex Hormones, Oncology, Respiratory, Gastrointestinal, Immunology, Central Nervous System and Metabolic Disorders which include indications Arterial Thrombosis, Renal Failure, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Emphysema, Focal Segmental Glomerulosclerosis (FSGS), Graft Versus Host Disease (GVHD), Hepatic Veno-Occlusive Disease, Idiopathic Pulmonary Fibrosis, Kidney Fibrosis, Liver Fibrosis, Metastatic Lung Cancer, Multiple Sclerosis, Non Alcoholic Fatty Liver Disease (NAFLD), Obesity, Pulmonary Fibrosis, Stroke, Systemic Sclerosis (Scleroderma), Thromboembolism, Thrombosis, Thrombotic Microangiopathy and Venous (Vein) Thrombosis.

The latest report Plasminogen Activator Inhibitor 1- Pipeline Review, H2 2018, outlays comprehensive information on the Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1)

- The report reviews Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) targeted therapeutics and enlists all their major and minor projects

- The report assesses Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Pipeline Review, H2 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Overview
Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Companies Involved in Therapeutics Development
CisThera Inc
Jazz Pharmaceuticals Plc
MDI Therapeutics Inc
Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Drug Profiles
Bispecific Antibody to Inhibit TAFI and PAI-1 for Thrombosis and Stroke - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CT-140 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
defibrotide sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide to Inhibit PAI-1 for Arterial Thrombosis and Pulmonary Thromboembolism - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SK-216 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit PAI1 for Immunology, Respiratory and Cardiovascular Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TM-5275 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TM-5441 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TM-5484 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TM-5614 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Dormant Products
Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Discontinued Products
Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Product Development Milestones
Featured News & Press Releases
Feb 23, 2018: Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Trial Evaluating Defibrotide for the Prevention of Acute Graft-versus-Host Disease
Nov 01, 2017: Jazz Pharmaceuticals to Present Abstracts on Defitelio at ASH 2017 Annual Meeting
Jan 17, 2017: Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Trial Evaluating Defibrotide for the Potential Prevention of VOD in High Risk Patients
Nov 07, 2016: Jazz Pharmaceuticals to Present New Data on Defitelio at the Annual ASH Meeting
Aug 02, 2016: CMS Grants New Technology Add-On Payment to Defitelio for the Treatment of Hepatic Veno-Occlusive Disease with Renal or Pulmonary Dysfunction Following Hematopoietic Stem-Cell Transplantation
Mar 30, 2016: FDA approves first treatment for rare disease in patients who receive stem cell transplant from blood or bone marrow
Mar 30, 2016: Jazz Pharmaceuticals Announces Webcast for Defitelio (defibrotide sodium) Investor Update
Feb 18, 2016: Jazz Pharmaceuticals To Present Data From Ongoing Evaluations Of Defibrotide At The 2016 BMT Tandem Meeting
Feb 01, 2016: Results from Phase 3 Trial of Defibrotide for the Treatment of Severe Veno-Occlusive Disease and Multi-Organ Failure Published Online in BLOOD
Sep 30, 2015: Jazz Pharmaceuticals Announces U.S. FDA Acceptance for Filing with Priority Review of NDA for Defibrotide for Hepatic Veno-Occlusive Disease
Feb 12, 2015: Jazz Pharmaceuticals to Present Data on Defibrotide, an Investigational Treatment, in Patients with Hepatic Veno-Occlusive Disease at BMT Tandem Meetings
Dec 11, 2014: Jazz Pharmaceuticals Initiates Rolling NDA Submission For Defibrotide For The Treatment Of Severe Hepatic Veno-Occlusive Disease
Dec 02, 2014: Jazz Pharmaceuticals To Present New Analysis Of Defibrotide Data In Patients With Hepatic Veno-Occlusive Disease (VOD) At ASH Annual Meeting
Mar 31, 2014: Jazz Pharmaceuticals And Gentium Announce European Commercial Launch Of First Approved Life-Saving Treatment For Severe Hepatic Veno-Occlusive Disease
Dec 11, 2013: Interim Results From Gentium's Treatment IND for Defibrotide and Additional Data on Defibrotide in the Prevention of Acute Graft Versus Host Disease Presented at the American Society of Hematology Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by CisThera Inc, H2 2018
Pipeline by Jazz Pharmaceuticals Plc, H2 2018
Pipeline by MDI Therapeutics Inc, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd..1), H2 2018
Discontinued Products, H2 2018

List of Figures
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Cancer Monoclonal Antibodies Market 2018, Forecast to 2023
    Published: 14-Dec-2018        Price: US 4880 Onwards        Pages: 119
    The mAbs, which are produced by genetic engineering, target antigens in cells, tissues, and organs. They are used in clinical applications to treat diseases with excellent efficacy and minimal side effects. Their MOA, absence of generic pathway, and therapeutic applications distinguish them from other targeted therapeutics. Scope of the Report: This report focuses on the Cancer Monoclonal Antibodies in global market, especially in North America, Europe and Asia-Pacific, Sou......
  • Global and Chinese Syphilis Rapid Test Kit Industry, 2018 Market Research Report
    Published: 14-Dec-2018        Price: US 3000 Onwards        Pages: 150
    The 'Global and Chinese Syphilis Rapid Test Kit Industry, 2013-2023 Market Research Report' is a professional and in-depth study on the current state of the global Syphilis Rapid Test Kit industry with a focus on the Chinese market. The report provides key statistics on the market status of the Syphilis Rapid Test Kit manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Firstly, the report provides a basic overview of the indu......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Cervical Cancer Drugs Market 2018, Forecast to 2023
    Published: 14-Dec-2018        Price: US 4880 Onwards        Pages: 130
    Cervical cancer is an uncontrolled growth of cells in the cervix region, which is accompanied by symptoms such as abnormal vaginal bleeding, pelvic pain, pain during sexual intercourse, and abnormal vaginal discharge. Scope of the Report: This report focuses on the Cervical Cancer Drugs in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and ap......
  • Global and Chinese Human Growth Hormone Industry, 2018 Market Research Report
    Published: 14-Dec-2018        Price: US 3000 Onwards        Pages: 139
    The 'Global and Chinese Human Growth Hormone Industry, 2013-2023 Market Research Report' is a professional and in-depth study on the current state of the global Human Growth Hormone industry with a focus on the Chinese market. The report provides key statistics on the market status of the Human Growth Hormone manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Firstly, the report provides a basic overview of the industry incl......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Chlorpheniramine Maleate Market 2018, Forecast to 2023
    Published: 14-Dec-2018        Price: US 4880 Onwards        Pages: 128
    Chlorpheniramine maleate is an alkylamine antihistamine which is used in the treatment of allergic conditions such as rhinitis and urticaria. Scope of the Report: This report focuses on the Chlorpheniramine Maleate in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application. This compound blocks histamine during allergic reaction......
  • Global and Chinese Active Pharmaceutical Ingredients Industry, 2018 Market Research Report
    Published: 14-Dec-2018        Price: US 3000 Onwards        Pages: 146
    The 'Global and Chinese Active Pharmaceutical Ingredients Industry, 2013-2023 Market Research Report' is a professional and in-depth study on the current state of the global Active Pharmaceutical Ingredients industry with a focus on the Chinese market. The report provides key statistics on the market status of the Active Pharmaceutical Ingredients manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Firstly, the report provide......
  • Global and Chinese Acyclovir Industry, 2018 Market Research Report
    Published: 14-Dec-2018        Price: US 3000 Onwards        Pages: 149
    The 'Global and Chinese Acyclovir Industry, 2013-2023 Market Research Report' is a professional and in-depth study on the current state of the global Acyclovir industry with a focus on the Chinese market. The report provides key statistics on the market status of the Acyclovir manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Firstly, the report provides a basic overview of the industry including its definition, application......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Cetrimide Market 2018, Forecast to 2023
    Published: 14-Dec-2018        Price: US 4880 Onwards        Pages: 137
    Cetrimide is an antiseptic agent, meaning it has various antibacterial, antifungal and other antimicrobial properties and can be applied to skin or mucous membranes to avoid or minimize the risk of infection. It is also a surfactant, meaning it functions as a detergent with cleaning properties. Scope of the Report: This report focuses on the Cetrimide in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report ......
  • Global and Chinese Bone Glues Industry, 2018 Market Research Report
    Published: 14-Dec-2018        Price: US 3000 Onwards        Pages: 137
    The 'Global and Chinese Bone Glues Industry, 2013-2023 Market Research Report' is a professional and in-depth study on the current state of the global Bone Glues industry with a focus on the Chinese market. The report provides key statistics on the market status of the Bone Glues manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Firstly, the report provides a basic overview of the industry including its definition, applicat......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs